OncoCyte Corp represents a commitment to advancing the field of cancer diagnostics. The company’s corporate philosophy focuses on developing innovative solutions to improve the early detection and treatment of cancer. OncoCyte Corp values scientific excellence, collaboration, and integrity in its pursuit of reliable and accurate diagnostic technologies. By leveraging cutting-edge research and technologies, OncoCyte Corp aims to provide physicians and patients with actionable insights for more effective diagnosis and personalized treatment planning. With a dedication to improving patient outcomes, OncoCyte Corp strives to make a meaningful impact in the fight against cancer.

OncoCyte Corp, a leading biotechnology company, primarily operates in the United States. With its headquarters in Alameda, California, OncoCyte focuses on the development and commercialization of novel diagnostics for early detection and monitoring of cancer. The company leverages advanced technologies for the detection of biomarkers associated with various cancers, including lung and breast cancer. OncoCyte aims to provide innovative diagnostic solutions to improve patient outcomes and revolutionize cancer care.

OncoCyte Corp has achieved several significant milestones. The company successfully developed and launched the non-invasive test, DetermaVu, a diagnostic tool designed to detect lung cancer. OncoCyte Corp also received a Breakthrough Device designation from the FDA for DetermaVu. In addition, the company collaborated with several renowned institutions and organizations for further research and development. OncoCyte Corp's dedication to advancing cancer diagnostics has positioned it as a key player in the industry. With ongoing efforts, the company continues to contribute to improving the detection and treatment of lung cancer.

OncoCyte Corp is a biotechnology company specializing in the development and commercialization of novel molecular diagnostic tests for the early detection of cancer. Established in 2009, OncoCyte has been committed to revolutionizing cancer diagnosis through its advanced technology and innovative approach. The company's focus lies in leveraging the power of liquid biopsies and specialized tests to provide accurate, reliable, and non-invasive cancer screening solutions. OncoCyte Corp aims to improve patient outcomes by detecting cancer at its earliest stages when treatment options are most effective. With a strong dedication to research and development, OncoCyte Corp continues to make significant strides in the field of early cancer detection.

The main competitors of OncoCyte Corp in the market include companies such as Exact Sciences Corporation, Genomic Health Inc., and Veracyte Inc.

OncoCyte Corp is primarily active in the biotechnology industry.

OncoCyte Corp is a medical technology company focused on the development and commercialization of innovative diagnostic tests for early detection of cancer. The company's business model revolves around the research and development of novel liquid biopsy and blood-based tests that detect and analyze biomarkers associated with various types of cancers. OncoCyte Corp aims to provide accurate, non-invasive, and cost-effective diagnostic solutions to aid in the detection and monitoring of cancer, ultimately improving patient outcomes. Through their cutting-edge technology and ongoing research efforts, OncoCyte Corp seeks to revolutionize cancer detection and contribute to the advancement of personalized medicine.

OncoCyte의 P/E 비율은 -0.65입니다.

OncoCyte의 P/S 비율은 30.03입니다.

OncoCyte에 대한 AlleAktien 품질 점수는 3/10입니다.

예상되는 OncoCyte 매출은 669,963.3 USD입니다.

예상되는 OncoCyte 이익은 -30.85 백만 USD입니다.

OncoCyte is a biotechnology company specialized in the development of diagnostic tests for cancer. They focus on research and development of diagnostic tests, commercialization and marketing of these tests, and creating partnerships with other companies and research institutions. They use modern technologies such as molecular diagnostics, next-generation sequencing, and immunohistochemistry in their research and development. Their goal is to offer their test solutions in different markets and expand their distribution network through collaborations. They have developed the LungENT diagnostic test for lung cancer and the DetermaIO test for predicting response to immunotherapies.

OncoCyte은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

OncoCyte의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

OncoCyte의 ISIN은 US68235C1071입니다.

OncoCyte의 WKN은 A2ACBH입니다.

OncoCyte의 티커는 OCX입니다.

지난 12개월 동안 OncoCyte은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 OncoCyte은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

OncoCyte의 현재 배당 수익률은 입니다.

OncoCyte은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

OncoCyte은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

OncoCyte은 '건강' 섹터에 속합니다.

OncoCyte의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 OncoCyte는 0 USD를 배당금으로 지급했습니다.

OncoCyte의 배당금은 USD에 지급됩니다.